Engot-Ov-6/Trinova-2: randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in Women with recurrent partially platinum-sensitive or resistant ovarian cancer.
Citations
Altmetric:
Abstract
Authors
Description
Date
2015
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Engot-Ov-6/Trinova-2: randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in Women with recurrent partially platinum-sensitive or resistant ovarian cancer. 2015, 25(9):97-99 Int J Gynecol Cancer